Obstructive valve thrombosis after transcatheter aortic valve replacement (TAVR) in Sneddon syndrome without antiphospholipid antibodies

BMJ Case Rep. 2023 Jun 12;16(6):e254309. doi: 10.1136/bcr-2022-254309.

Abstract

We study a case of early obstructive leaflet thrombosis following a transcatheter aortic valve replacement (TAVR) in a woman in her 50s with a history of Sneddon syndrome treated by antiplatelet therapy. The thrombosis regressed following the use of vitamin K antagonists (VKA) for 6 weeks. Subacute TAVR leaflet thrombosis reappeared after discontinuation of VKA use. The main takeaways of this study were the detection of high-risk patients that could benefit from systematic post-TAVR anticoagulation and the early diagnosis of obstructive leaflet thrombosis associated with elevated transvalvular gradient, whose management differs from that of subclinical leaflet thrombosis.

Keywords: Interventional cardiology; Valvar diseases.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antiphospholipid
  • Anticoagulants
  • Catheters
  • Female
  • Fibrinolytic Agents
  • Humans
  • Sneddon Syndrome*
  • Thrombosis*
  • Transcatheter Aortic Valve Replacement*

Substances

  • Antibodies, Antiphospholipid
  • Anticoagulants
  • Fibrinolytic Agents